- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 403/12
Total number of patents in this class: 9838
10-year publication summary
|
603
|
556
|
597
|
550
|
623
|
597
|
559
|
687
|
580
|
468
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4826 |
206 |
| Boehringer Ingelheim International GmbH | 4636 |
158 |
| F. Hoffmann-La Roche AG | 7937 |
140 |
| Novartis AG | 10612 |
130 |
| Janssen Pharmaceutica N.V. | 3358 |
111 |
| Vertex Pharmaceuticals Incorporated | 1630 |
102 |
| BASF SE | 21098 |
99 |
| AstraZeneca AB | 2857 |
93 |
| Hoffmann-La Roche Inc. | 3546 |
92 |
| Merck Sharp & Dohme LLC | 3732 |
87 |
| Genentech, Inc. | 4016 |
85 |
| Pfizer Inc. | 3401 |
85 |
| Merck Patent GmbH | 5752 |
84 |
| Takeda Pharmaceutical Company Limited | 2721 |
74 |
| Gilead Sciences, Inc. | 2106 |
71 |
| Bayer AG | 3401 |
61 |
| Dana-Farber Cancer Institute, Inc. | 2626 |
61 |
| Amgen Inc. | 4256 |
60 |
| Array BioPharma Inc. | 475 |
56 |
| Rigel Pharmaceuticals, Inc. | 530 |
55 |
| Other owners | 7928 |